CurrentNeighborhood Health Plan of Rhode IslandPolicy 2089-A

Cystagon (cysteamine bitartrate) — Prior Authorization and Coverage Criteria

Covers prior authorization criteria and documentation requirements for Cystagon (cysteamine bitartrate) for treatment of nephropathic cystinosis for Neighborhood Health Plan of Rhode Island members.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyCystagon (cysteamine bitartrate) — Prior Authorization and Coverage Criteria

Policy CodePolicy 2089-A

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionSubmit initial prior authorization with leukocyte cystine assay or genetic testing confirming nephropathic cystinosis and documentation that Cystagon will not be used with Procysbi.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthsauthorization duration

Cystagondrug covered

nephropathic cystinosiscovered indication

Coverage Criteria for Cystagon (cysteamine bitartrate)

Initial Therapy

Covered when ALL of the following are met:

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial authorization requirements: Diagnosis of cystinosis confirmed by increased leukocyte cystine concentration assay or genetic testing; Prescribed by or in consultation with a physician who specializes in metabolic disease and/or lysosomal storage disorders; Member will not use Cystagon in combination with Procysbi.

Authorization granted for 12 months when criteria met

Continuation Therapy

Covered when ALL of the following are met:

Reauthorization requirements: Member previously authorized for an indication listed in Coverage Criteria (nephropathic cystinosis); Documentation of response to therapy (e.g., improvement, stabilization, or slowing of disease progression demonstrated by serum creatinine, calculated creatinine clearance, leukocyte cystine concentration, or maintained growth/height); Prescribed by or in consultation with a physician who specializes in metabolic disease and/or lysosomal storage disorders.

Authorization of 12 months may be granted

All indications other than nephropathic cystinosis are considered experimental/investigational and not medically necessary.

Use of Cystagon for indications other than nephropathic cystinosis is not medically necessary.

Provider Requirements, Documentation, and Authorization Rules

Prior Authorization

Initial authorization: diagnosis and duration

Authorization of up to 12 months may be granted when diagnosis is confirmed by increased leukocyte cystine concentration assay or by genetic testing, and the member will not use Cystagon in combination with Procysbi.

Prior Authorization

Reauthorization: documentation of response required

Authorization of up to 12 months may be granted for continued treatment when the member is responding to therapy, demonstrated by improvement, stabilization, or slowing of disease progression as evidenced by relevant labs or maintained growth/height.

Step Therapy

Step therapy note: no steps specified; combination prohibited

No step therapy is specified; however, Cystagon must not be used in combination with Procysbi.

Documentation Required

Required documentation for initial and continuation requests

Initial requests must include an assay showing increased cystine concentration in leukocytes or genetic testing results supporting the diagnosis. Continuation requests must include lab results or chart notes documenting a positive response to therapy (e.g., improvement, stabilization, or slowing of disease progression for serum creatinine, calculated creatinine clearance, leukocyte cystine concentration, or maintained growth/height).

Documentation Required

Prescriber specialty requirement

Medication must be prescribed by or in consultation with a physician who specializes in the treatment of metabolic disease and/or lysosomal storage disorders.

Denial Risk

Non‑covered indications: limited to nephropathic cystinosis

Requests for indications other than nephropathic cystinosis are considered experimental/investigational and not medically necessary; such requests may be denied.

Denial Risk

Forbidden combination with Procysbi

Use of Cystagon in combination with Procysbi is not permitted and may result in denial of the request.

Background

Nephropathic cystinosis is treated with cysteamine to reduce intracellular cystine accumulation. Cystagon (cysteamine bitartrate) is FDA‑approved for the management of nephropathic cystinosis in children and adults; other uses are considered experimental/investigational and not medically necessary.

Definitions and Diagnostic Criteria

Cystagon — drug identification

Brand nameCystagon

Generic namecysteamine bitartrate

ScopeAll brand and generic forms, all dosage forms and strengths unless otherwise stated

Diagnostic confirmation required

Acceptable diagnostic testsAssay detecting increased cystine concentration in leukocytes

Alternative confirmationGenetic testing results supporting a diagnosis of cystinosis

Required submission for initial requestsInclude assay or genetic testing results with prior authorization request